SCHEMBL9073785

SCHEMBL9073785

CS(=O)(=O)N1CCC(=C2c3ccccc3CCc3cccnc32)CC1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FNTA P49354 11/20 0.76
FNTB P49356 11/20 0.76
HRH1 P35367 3/20 0.72
CHRM2 P08172 1/20 0.72
HTR1A P08908 1/20 0.72
CHRM1 P11229 1/20 0.72
DRD2 P14416 1/20 0.72
HTR2A P28223 1/20 0.72
HTR2C P28335 1/20 0.72
ADRA1A P35348 1/20 0.72
OPRK1 P41145 1/20 0.72
HTR2B P41595 1/20 0.72
KCNH2 Q12809 1/20 0.72
PTAFR P25105 9/20 0.67
SLC6A15 Q9H2J7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29626521 0.86 FNTA (1.00) FNTAFNTBHRH1PTAFRSLC6A15
SCHEMBL23303105 0.86 FNTA (1.00) FNTAFNTBHRH1PTAFRSLC6A15
Azatadine SCHEMBL3721 0.84 HRH1 (1.00) FNTAFNTBHRH1CHRM2HTR1A
Azatadine SCHEMBL29746602 0.84 HRH1 (1.00) FNTAFNTBHRH1CHRM2HTR1A
Azatadine SCHEMBL29363595 0.84 HRH1 (1.00) FNTAFNTBHRH1CHRM2HTR1A
Azatadine SCHEMBL6061443 0.83 HRH1 (0.97) FNTAFNTBHRH1CHRM2HTR1A
SCHEMBL8877892 0.80 PTAFR (1.00) FNTAFNTBHRH1CHRM2HTR1A
SCHEMBL13937027 0.80 HRH1 (0.76) FNTAFNTBHRH1CHRM2HTR1A
SCHEMBL9215889 0.79 HRH1 (0.89) FNTAFNTBHRH1CHRM2HTR1A
SCHEMBL9073792 0.77 HRH1 (0.80) FNTAFNTBHRH1CHRM2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0563134-B1 AGENTS FOR POTENTIATING THE EFFECTS OF ANTITUMOR AGENTS AND COMBATING MULTIPLE DRUG RESISTANCE WELLCOME FOUND (GB) 1996-06-19 EP claimed
US-5416091-A Agents for potentiating the effects of antitumor agents and combating multiple drug resistance BURROUGHS WELLCOME CO. (US) 1995-05-16 US claimed
EP-0042544-B1 NOVEL ANTIHISTAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1984-10-03 EP claimed
EP-0042544-A2 Novel antihistamines, process for their preparation and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1981-12-30 EP claimed
US-4282233-A NO SEDATIVE EFFECT SCHERING CORPORATION (US) 1981-08-04 US claimed
EP-0563134-B1 AGENTS FOR POTENTIATING THE EFFECTS OF ANTITUMOR AGENTS AND COMBATING MULTIPLE DRUG RESISTANCE WELLCOME FOUND (GB) 1996-06-19 EP disclosed
US-5416091-A Agents for potentiating the effects of antitumor agents and combating multiple drug resistance BURROUGHS WELLCOME CO. (US) 1995-05-16 US disclosed
US-4831042-A Tricyclic-substituted piperidine antihistamines SCHERING CORPORATION (US) 1989-05-16 US disclosed
US-4560688-A NON-SEDATING; CARBAMOYL OR SULFONAMIDE DERIVATIVES SCHERING CORPORATION (US) 1985-12-24 US disclosed
US-4454143-A Tricyclic antihistamines SCHERING CORPORATION (US) 1984-06-12 US disclosed
US-4355036-A Tricyclic-substituted piperidine antihistamines SCHERING CORPORATION (US) 1982-10-19 US disclosed
US-4282233-A NO SEDATIVE EFFECT SCHERING CORPORATION (US) 1981-08-04 US disclosed